INO-4201 / Inovio  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
INO-4201 / Inovio
NCT02464670: Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers

Completed
1
240
US
INO-4201, INO-4202, INO-4212, INO-4212 + INO-9012, INO-4201 + INO-9012
Inovio Pharmaceuticals, GeneOne Life Science, Inc., Defense Advanced Research Projects Agency
Ebola Vaccine
05/18
05/18
Boost-EBOV, NCT04906629: INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees

Completed
1
46
Europe
INO-4201, Placebo
University of Geneva, Switzerland, Defense Advanced Research Projects Agency, Global Urgent and Advanced Research and Development (GuardRX), Inovio Pharmaceuticals
Ebola Virus Disease
01/22
05/22

Download Options